Recent perioperative challenges in anesthesia during expansion of heart transplantation Authors: Anthony Wang, Nasir Hussain, Amardeep Mudhar, James Robbins, Joseph Friessen, Andrew Hicks, Sree Satyapriya, Bryan Whitson, Sujatha Bhandary, Maziar Khorsandi, Hamdy Awad Published: 2026 ABSTRACT The evolving landscape of heart transplantation requires cardiac anesthesiologists to adapt to new paradigms aimed at expanding donor and recipient pools such as utilizing more donor hearts from older donors, those with higher BMI, left ventricular hypertrophy (LVH), or coronary artery disease, as well as grafts obtained through long-distance procurement and from donors with infectious conditions such as hepatitis C, COVID-19, and HIV. The promising use of devices such as Organ Care System (OCS), Paragonix SherpaPak (SCTS), and Hypothermic Oxygenated Machine Perfusion (HOPE) for preservation of donor hearts, as well as recent increases in donation after circulatory death (DCD) transplants, exemplifies these advancements. In particular, the introduction of beating heart DCD transplants offers the opportunity to minimize ischemic times. However, perioperative complications such as catecholamine-sensitive and resistant vasoplegia, acute right-sided heart dysfunction, primary graft dysfunction (PGD), surgical bleeding, and coagulopathy complicate the picture. The expansion of donor and recipient pools increases the risk of ischemia and reperfusion injury. Despite these challenges, cardiac anesthesiologists must be vigilant in recognizing and managing these complications to ensure the best short and long-term outcomes. For example, novel prediction tools for PGD such as RADIAL and PREDICTA may assist in facilitating earlier intervention in high-risk patients. Finally, the interplay between surgical bleeding, vasoplegia, acute RV dysfunction/failure, and PGD immediately post-transplant provides a significant challenge to cardiac anesthesiologists. By addressing these challenges, they can improve outcomes and play a pivotal role in advancing heart transplantation. Their efforts will make the expansion worthwhile, increasing the availability of donor hearts and enhancing patient care. Background Currently, heart transplantation remains the gold-standard intervention for end-stage heart failure that is refractory to medical management. According to the United Network for Organ sharing (UNOS), there were approximately 4,587 heart transplants performed in the United States in 2025, which is the largest ever annual number for this procedure [1]. However, as with most other organ transplants, a significant gap remains between the available donor hearts and suitable recipients. At the time of publication, there are currently 3,902 candidates awaiting a suitable heart for transplant. Median wait times for transplantation vary based on a number of factors such as age and blood type, ranging from 76 to 726 days based on the patient’s United Network for Organ Sharing (UNOS) heart status level in data collected from 2011 to 2014 [1]. With such a high demand for heart transplantation, the medical community continues to investigate ways to expand both the donor and recipient pools for this surgery. Currently, no formal national guidelines establish strict criteria for donor or recipient eligibility. As a result, many hospital systems set their own guidelines for donors and recipients, though these rules will often look similar to other transplant centers. Subsequently, donor and recipient eligibility criteria have expanded in order to accommodate the increased demand for this procedure. The increasing willingness to reexamine factors such as age, donation after circulatory death, and infectious states of both donor and recipient hearts will inevitably lead to more transplants, but also more perioperative complications facing cardiac anesthesiologists. Some of these-including vasoplegia, acute right heart dysfunction/failure, surgical bleeding, coagulopathy-combined with the possibility of primary graft dysfunction (PGD), complicate the picture for the cardiac anesthesiologists dealing with one or multiple of these complications immediately post-cardiopulmonary bypass (CPB). Cardiac anesthesiologists will face these new challenges immediately post-transplant due to this expansion of utilizing more marginal hearts and transplanting higher-risk patients. As a result, they will need to recognize high-risk patients and their need for close monitoring, pharmacological support, and possible immediate transition to mechanical support to ensure the best clinical outcomes in both the short and long-term. Expansion of heart transplant donor pools using expanded criteria donors We will discuss the effects of heart donor age on the recipient, donor hearts with left ventricular hypertrophy (LVH), hearts from high-BMI donors, mild to moderate donor coronary artery disease (CAD), infectious pathologies (Hepatitis C, HIV, and COVID-19) on both the donor and recipient, and the increased number of hearts obtained from donation after circulatory death (DCD). Overall, anesthesiologists need to communicate with the transplant coordinators and cardiac surgeons regarding the risk factors of donor BMI, donor CAD, donor and recipient infectious pathologies, and the cause of death of the donor in order to be best prepared for potential complications. Transplanting hearts from donors of older age and implications for long-distance procurement Currently, there are no set federal guidelines in the United States regarding age restrictions in heart donation. For many hospitals, the cutoff for heart transplant donors remains around 50–55 years old [2]. However, recent studies suggest that expanding the donor age for heart transplantation can be a viable option to increase the donor pool. Two separate retrospective analyses found that using hearts from older donors (≥ 50 years, n = 162 and ≥ 55 years, n = 832 respectively) did not have a significant impact on 1-, 3-, and 5-year survival compared to younger donors. However, both found there was a higher incidence in cardiac allograft vasculopathy (CAV) in the older donor groups (freedom from CAV at 8 years 65 ± 18 vs. 78 ± 7%; P = 0.06 and freedom from CAV at one year 87.9 vs. 94.8, p = 0.022 respectively) [3, 4]. CAV is defined as remodeling of cardiac vasculature after heart transplant that occurs due to intimal hyperplasia. It is diagnosed through angiography or intravascular ultrasonography [5]. Reich et al. found that recipients of older hearts (≥ 50 years) with short cold ischemic times (CITs) of less than 120 min had similar 5-year recipient or graft survival rates (80% older vs. 85.6% younger; P = 0.79), freedom from nonfatal major adverse cardiac events (83.3% vs. 91.5%; P = 0.46), and freedom from cardiac allograft vasculopathy (50% vs. 70.6%; P = 0.66) [6]. Rejection rates were mostly similar to those who received younger hearts (< 50 years) with CITs under 120 min. However, recipients of older hearts with CITs between 120 and 240 min or over 240 min had worse 5-year outcomes compared to recipients of younger hearts in the same CIT groups [6]. However, the ability to maintain relatively short CITs is increasingly challenged in the current allocation era, where donor hearts may arrive from a wider geographic range. As a result, the interaction between donor characteristics such as age and ischemic time has become even more clinically relevant. In 2018, UNOS heart allocation policy changes prioritized medical urgency over geographic proximity, resulting in increased procurement distances and longer CITs [7, 8]. Under the current allocation policy, donor hearts within a 500-mile radius are prioritized for high-priority candidates with the aim of keeping ischemic time within a common 4-hour benchmark [9]. However, average ischemic times have increased from 3.0 to 3.4 h following the 2018 policy change, and ischemic times > 6 h are more common in the new era (22.1% vs. 18.5%; p<0.001) [7, 10]. The effect of ischemic time on survival after heart transplantation is dependent on donor age, with greater tolerance for prolonged ischemic times among grafts from younger donors. For example, in donors younger than 18 years, no significant differences in survival or graft failure were apparent across different CIT groups, even with CIT exceeding 6 h [11]. However, for donors older than 18 years, significant differences were found for survival and graft failure with CIT exceeding 4 h in both univariate and multivariate analysis [11]. Additionally, hearts from older donors (≥ 35 years) are more susceptible to ischemia-reperfusion injury than those of younger donors [12]. However, Nordan et al. found that under the new allocation system, effect of ischemic time ≥ 4 h on mortality when donor age is ≥ 39 years was insignificant (90.4% vs. 91.1%, log-rank P = 0.73). This was likely due to increased transplantation of these organs in less emergent, more stable recipients [13]. Overall, these findings suggest that expanding the donor age for heart transplantation can be considered to expand the donor pool, but careful recipient selection, management of CIT, and monitoring for CAV in high-risk cases are key factors for cardiac anesthesiologists to consider and inquire about preoperatively. Additionally, cardiac anesthesiologists should inquire preoperatively about the anticipated or actual CIT and procurement distance, as these factors influence the risk of primary graft dysfunction and early hemodynamic instability [7, 9, 12]. Transplanting hearts with LVH Donor LVH is a common reason for organ exclusion despite growing evidence that it does not significantly impact post-transplant outcomes [14, 15]. According to the American Society of Echocardiography guidelines, LVH is classified by interventricular septal or posterior LV wall thickness: normal (1.1 cm), mild (1.1–1.3 cm), and moderate-to-severe (≥ 1.4 cm) [16]. Consensus guidelines suggest that if wall thickness is 1.4 cm and there are no electrocardiographic findings consistent with LVH, the use of such a donor may be appropriate [17]. However, close to half of all transplanted allografts demonstrate some degree of LVH, and utilization of moderate-to-severe LVH donor hearts has declined over time (β − 1.62%/yr; p = 0.012), suggesting program-dependent hesitation despite favorable data [18, 19]. Several studies support the safety of transplanting hearts with donor LVH. A UNOS registry analysis of 2,626 patients found that mild LVH was present in 38% and moderate-severe LVH in 5.6% of allografts while LVH did not predict mortality at 30 days or 1-year post-transplant [18]. However, subgroup analyses showed an increased risk of death in recipients of allografts with LVH combined with donor age > 55 years or ischemic time ≥ 4 h [18]. A more recent UNOS registry analysis of 8,058 recipients (2018–2024) confirmed these findings, demonstrating that survival was similar across all LVH groups at 30-day (p = 0.531), 1-year (p = 0.336), and 3-years (p = 0.343) [19]. In multivariate analysis, neither mild (HR 0.95; p = 0.447) nor moderate-severe LVH (HR 1.02; p = 0.772) predicted higher 3-year mortality or acute rejection (p = 0.678) [19]. Importantly, even across high-risk subgroups including donor age > 55 years, ischemic time > 4 h, DCD status, and ECMO bridge-to-transplant, 3-year survival remained comparable between recipients of LVH and non-LVH donor hearts [19]. Similarly, an analysis of 14,584 adult heart transplant recipients from the Scientific Registry of Transplant Recipients (2015–2022) found that donor LVH was not linked to graft survival in unadjusted or adjusted analyses and concluded that LVH should not be a sole reason for donor heart exclusion [14]. A single-center study of 427 heart transplant recipients further demonstrated that 53% of donors had moderate LVH (septum or posterior wall > 1.3–1.7 cm) and 5% had severe LVH (wall thickness > 1.7 cm), with no significant differences in 30-day, 1-year, or long-term survival between recipients with and without donor LVH [15]. Multivariable Cox regression analysis found that donor LVH was not associated with risk of death and even had some protective effect [15]. Notably, all recipients with donor LVH in this cohort had ischemic times over 240 min. Additionally, recipients of younger donor hearts with LVH had the best survival rates, suggesting that many of these hearts had physiologic rather than pathologic hypertrophy. However, a history of donor hypertension in those recipients with donor LVH was found to have an unfavorable impact on late survival, suggesting that these patients had more advanced changes in myocardial structure and diastolic function [15]. An important consideration is that donor LVH appears to regress after transplantation. In one study, LV wall thickness at 1- and 5-year follow-up was similar in recipients of donor hearts with and without LVH, indicating regression of hypertrophy after transplantation [15]. This regression may be facilitated by antihypertensive therapy in the post-transplant period, as in this study, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were demonstrated to lead to regression of LVH regardless of blood pressure control [15]. It is also important to note that measured wall thickness at the time of organ donation is subject to loading conditions, which may overestimate the degree of true LVH in the donor. These findings suggest that expanding donor acceptance criteria to include hearts with LVH has the potential to meaningfully increase the donor pool without compromising recipient survival. However, careful evaluation of donor comorbidities, particularly hypertension, donor age, and anticipated ischemic time—remains important. Anesthesiologists should inquire about the degree of donor LVH, the presence of donor hypertension, and the anticipated ischemic time preoperatively, as the combination of these factors may influence early graft function and hemodynamic management after cardiopulmonary bypass [18–20]. In the early post-transplant period, anesthesiologists should be aware that hearts with LVH may have altered diastolic function, and intraoperative transesophageal echocardiography can be used to assess wall thickness, diastolic filling patterns, and ventricular function after weaning from bypass. Donor-recipient size matching: the role of predicted heart mass and severe donor obesity Donor-recipient size matching is a critical aspect of donor heart evaluation and has traditionally relied on body weight-based criteria. Currently, International Society for Heart and Lung Transplantation (ISHLT) guidelines recommend that donor body weight should be within 30% of the recipient’s body weight [17]. However, these same guidelines also recommend utilizing predicted heart mass (PHM), which has emerged as a superior technique for donor-recipient size matching, outperforming traditional metrics including weight, height, BMI, and body surface area in predicting post-transplant outcomes [21, 22]. In a study of 19,168 adult heart transplant recipients, PHM was the only size-matching metric that predicted 1-year mortality when severely undersized (donor-recipient PHM ratio 0.86, hazard ratio 1.34, p < 0.001), while undersizing by weight, height, BMI, or BSA did not predict increased mortality [22]. Importantly, 32% of potential donor hearts rejected for size concerns would have been acceptable using PHM criteria, and many donor-recipient pairs with weight mismatch > 30% had an acceptable PHM ratio, suggesting that PHM-based matching could expand the donor pool while improving post-transplant survival [21, 22]. The association between PHM mismatch and outcomes seems to follow a U-shaped pattern. Severe undersizing (PHM ratio 0.86) increases 1-year mortality, while extreme oversizing (total ventricular mass > 50%) is also associated with worse 1-year survival (hazard ratio 1.40, p = 0.004) and increased incidence of postoperative stroke [23]. Recent work has further refined this approach by separately assessing left ventricular (LV) and right ventricular (RV) PHM, showing that graft failure risk increases incrementally when LV PHM is undersized by more than 5% and when RV is oversized by more than 20% [24]. Notably, the impact of undersized PHM ratio hearts appears to be driven primarily by complex transplant operations (preoperative left ventricular assist device, adult congenital heart disease, or preoperative extracorporeal membrane oxygenation), while recipients of undersized hearts from noncomplex transplant operations had similar hemodynamic profiles and survival as those who received matched and oversized hearts [25]. Many transplant centers may be hesitant to transplant hearts from donors with severe obesity (BMI ≥ 40) due to concerns regarding heart size-matching and early mortality post-transplant [26]. As mentioned previously, ISHLT guidelines recommend that donor body weight should be within 30% of the recipient’s body weight [17]. However, as the population of the United States becomes more obese over time, this could preclude many potential hearts from being transplanted. Recent studies have demonstrated no significant difference in short-term complications, 1-year incidence of graft failure and survival, and long-term survival (up to 10 years post-transplant) [27, 28]. Additionally, Krebs at a. found no significant difference in long-term survival up to 10 years post-transplant between obese donors with BMI over or below 40 [28]. Overall, cardiac anesthesiologists should inquire preoperatively about the donor-recipient PHM ratio, as this is now the preferred size-matching metric and can help anticipate potential complications. Understanding whether a donor heart is significantly undersized (PHM ratio 0.86) or oversized (> 50% by total ventricular mass) can inform expectations regarding primary graft dysfunction or hemodynamic instability in the early post-transplant period [22–24]. Additionally, cardiac anesthesiologists should be aware of donor BMI (among other measurements such as height, weight, and body surface area), and the complexity of the transplant operation (such as presence of preoperative mechanical circulatory support) to be best prepared for potential complications, as these factors can interact with size matching to influence outcomes. Transplanting hearts from donors with coronary artery disease (CAD) The presence or suspicion of CAD in donor hearts has often been a contraindication to transplant in many transplant centers. One study looking at California Transplant Donor Network data from 2001 to 2008 showed that 91% of donor hearts with CAD were not accepted for transplant [29]. Additionally, ISHLT guidelines state that donor hearts with obstruction in at least one major coronary artery should be avoided unless the recipient has marginal characteristics or is facing imminent death and is also undergoing concomitant coronary bypass surgery [17]. Previous studies identified pre-existing CAD in donor hearts as a possible risk factor for new cardiac allograft vasculopathy (CAV) within 3 years [30]. However, more recent data has demonstrated no difference in 30 day, 1-year, and 10-year survival between recipients who received CAD hearts vs. those who received CAD-free hearts, though the severity of CAD was often not differentiated [31, 32]. Another study by Lechiancole et al. showed no difference in freedom from CAV and cardiac-related adverse events at 5- and 10-years post-transplant between CAD and non-CAD donor hearts [33]. Thus, using donor hearts with mild to moderate CAD may increase the donor pool. However, cardiac anesthesiologists should still be aware if there is any significant CAD in the donor heart in special circumstances and remain vigilant regarding immediate graft dysfunction due to significant CAD. Overall, cardiac anesthesiologists need to be aware of the short and long-term effects of age, obesity, and CAD on the quality of the transplanted heart and prepare to deal with any perioperative complications that can occur as a result of more marginal donor hearts. Transplanting hearts from donors who are hepatitis C (HCV) positive There has been a growing interest in both using more HCV+ donor hearts and HCV+ recipients. Recent advances in treatment, most notably direct-acting antivirals, have made 90% of cases curable [34]. Previously, recipients receiving HCV+ hearts were at higher risk of mortality due to viral hepatitis, liver failure, and coronary artery disease [35]. However, the introduction of antiretrovirals has made HCV + heart transplant more feasible as cure rates post-transplant can approach 95% [36–38]. Dharmavaram et al. found that since 1995 in the U.S., the number of heart transplants utilizing HCV+ donor organs has steadily risen, possibly due to drug overdose deaths in the recent opioid epidemic [39]. In a study of 343 heart transplants involving HCV + donors, Killic et al. found that 1-year survival rates were similar between recipients with HCV + and HCV- donor hearts (89.8% HCV− versus 89.2% HCV+; P = 0.88) [40]. There were also no significant differences in postoperative new-onset dialysis, stroke, or length of hospital stay [40]. Long-term studies are still needed. In contrast, the data for transplanting hearts into HCV+ recipients is more mixed. From 2011 to 2014 in the U.S., approximately 1.7% of recipients were HCV+ [41]. Quader et al. found in a review of 778 heart transplants that post-transplant survival in HCV+ recipients increased from 1991 (81.0% (1 year), 73.3% (2 years), and 61.4% (5 years)) to 2014 (89.01% (1 year) and 81.89% (2 years)) as new HCV treatments became available [41]. Some studies have found long-term post-transplant survival in HCV+ recipients is significantly lower compared to HCV- recipients [42, 43]. Other studies have similar short-term post-transplant survival between the two groups [41, 44]. As the number of transplants involving HCV+ donor organs or recipients inevitably increases, cardiac anesthesiologists must continue to be cautious of the risks of accidental exposure of bloodborne pathogens and mitigate these risks with proper personal protective equipment and infection control. Transplanting hearts from donors who are COVID-19 positive Data for COVID-19’s effect on heart transplantation is more limited due to the outbreak’s recency. Indeed, there exists a concern for viral transmission from COVID-19 positive donor myocardium [45]. Vadiya et al. found that in the U.S., 122 out of 7698 (2.3%) of adult heart donors tested positive for COVID-19 within 14 days prior to donation from 2020 to 2022. The same study found no significant differences in post-transplant length of stay, acute rejection prior to discharge, 90-day survival, and follow-up left ventricular ejection fraction (LVEF) between patients receiving COVID-19 + and patients receiving COVID-19 - donor hearts [46]. Kim et al. found similar median lengths of stay, rates of acute graft failure, 30-day mortality, and 90-day mortality between these same two groups, which is encouraging for other centers transplanting COVID+ donor hearts [47]. Bottio et al. found that 47 total COVID-19 + recipients from several centers in Northern Italy had post-operative mortality double that of the general population [48]. However, these deaths were all due to post-operative respiratory failure from infection of multiple etiologies, except for one case being multi-organ failure. The high mortality in this study appears to be unrelated to allograft dysfunction or rejection, as no significant cases were reported. However, another study of multiple transplant centers in Germany found that recipients with severe post-transplant complications or high mortality also exhibited RV dysfunction, tricuspid regurgitation, and elevated pulmonary artery pressure. Thus, there may be a cardiovascular component to COVID-19 complications as well [49]. Additionally, another study observed no significant differences in one-year outcomes when transplanting COVID-19-positive donor hearts in the United States [50]. However, more long-term studies are needed. For anesthesiologists, it seems perioperative infection control would be the best prevention of morbidity and mortality in COVID-19 + recipients, but they should continue to know the vaccination status of the heart’s donor. Altered immune response as a result of COVID-19 in the recipient may also cause chest pain, ST-elevation, decompensated heart failure, cardiogenic shock, and rejection in recipients [51]. Cardiac anesthesiologists should continue to be cautious of this possibility. Transplanting hearts into HIV positive recipients With the advent of combined antiretroviral therapy, the lifespan of the HIV+ population has increased significantly [52]. However, as these patients live longer, the prevalence of cardiovascular disease and heart failure has also increased [53]. The number of heart transplants in HIV+ recipients is extremely limited due to concern regarding the impact of post-transplant immunosuppressive pharmacology, as well as potential interactions with antiretroviral therapy [54]. In fact, the first heart transplant involving an HIV+ recipient was not performed until 2003 [54]. Additionally, between 2004 and 2017, it was found that only 24 centers were performing heart transplants in HIV+ recipients in the United States, meaning that over 80% of centers were not [55]. In a retrospective analysis of heart transplants recorded in UNOS, Doberne et al. compared the outcomes between HIV+ recipients (n = 75) and HIV- recipients (n = 29,848). It was found that the former had longer hospital stays (18 days, IQR 12–31; 15 days, IQR 11–23 respectively), higher rates of acute rejection during initial hospitalization (38.7% vs. 17.7%, p < 0.001), and higher rates of receiving intravenous immunoglobulin (IVIG) or plasmapheresis for treatment of rejection (26.7% vs. 10.4%, p < 0.001). Despite these comorbidities, the same study found that there was no significant difference in 30-day, 1-year, and 5-year survival between the two groups (96.0%, 88.1%, and 80.2%, respectively for HIV+ recipients; 96.1%, 90.1%, and 78.2%, respectively in HIV- recipients) [53]. In another study, Madan et al. performed a retrospective analysis using UNOS data between 2004 and 2017 involving 41 HIV+ heart transplant recipients. When compared with 41 HIV- recipients matched for idiopathic dilated cardiomyopathy, there was no significant difference in survival five years post-transplant (Cox HR = 0.91 [95% CI: 0.33–2.50], P = 0.849). Additionally, there was no significant difference in those bridged with a ventricular‐assist device (n = 22) and those who were not bridged (n = 19) five years post-transplant (Cox hazard ratio [HR] = 0.32 [95% CI: 0.06‐1.64], P = 0.170) [55]. Overall, cardiac anesthesiologists must remain vigilant for signs of acute rejection in the immediate post-transplant period for HIV+ recipients. If such a phenomenon is identified, they must notify the transplant team immediately so that interventions such as IVIG and/or plasmapheresis can be implemented as soon as possible. Overall, cardiac anesthesiologists need to be aware of the short and long-term effects of HCV, COVID-19, and HIV on the quality of the transplanted heart. Advances in heart procurement and preservation Donation after circulatory death (DCD) Currently, donation after brain death (DBD) is the most common method of heart transplantation. In the United States, this has been defined since 1981 through the Uniform Determination of Death Act. This is a model state law that was approved by the National Conference of Commissioners on Uniform State Laws, the American Medical Association, the American Bar Association, and the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research [56]. It states that brain death is: An individual who has sustained either (1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, including the brain stem, is dead. A determination of death must be made in accordance with accepted medical standards. In contrast, the United Kingdom defines brain death in A Code of Practice for the diagnosis and confirmation of death that was last revised in 2025 by the Academy of Medical Royal Colleges [57]. In DBD heart transplants, the donor has been declared brain dead, but their cardiac function is largely intact with support. Thus, the donor heart can be removed while the heart is still well perfused, minimizing ischemic times. As stated above, there are currently no concrete guidelines for donor qualifications. Recently in 2023, Copeland et al. suggested donor heart selection guidelines for DBD transplants based on expert consensus and prior evidence [58]. Their suggested hemodynamic targets for DBD hearts consist of: Mean arterial pressure > 60 mmHg.Cardiac index > 2.4 L/min/m2.Central venous pressure < 12 mmHg.Pulmonary capillary wedge pressure < 12 mmHg.Left ventricular (LV) stroke work index > 15 g·min/m2. Mean arterial pressure > 60 mmHg. Mean arterial pressure > 60 mmHg. Cardiac index > 2.4 L/min/m2. Cardiac index > 2.4 L/min/m2. Central venous pressure < 12 mmHg. Central venous pressure < 12 mmHg. Pulmonary capillary wedge pressure < 12 mmHg. Pulmonary capillary wedge pressure < 12 mmHg. Left ventricular (LV) stroke work index > 15 g·min/m2. Left ventricular (LV) stroke work index > 15 g·min/m2. As the demand for heart transplantation increases, however, transplant sites have been performing more DCD transplantations [1]. In these cases, death is declared after irreversible loss of circulatory and pulmonary function. A standoff period (usually 5 min) is observed after circulatory death is declared before moving on to heart procurement. For DCD donors, direct procurement and perfusion (DPP) is a method that is commonly employed. Here, the donor heart is quickly removed from the body after observation and placed in a normothermic ex-vivo perfusion device such as the TransMedics Organ Care System (OCS). This allows the organ to be supported in a controlled and supported environment while awaiting transplant. The other, less commonly used method of DCD is normothermic regional perfusion (NRP), which utilizes Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) to restore circulation in the body while excluding the brain. Once the heart is deemed viable, it can be procured and transplanted. The outcomes between these two techniques appear to be similar, with studies demonstrating no significant difference in 1-year survival, pharmacologic or mechanical support, ventilation duration, and length of ICU or hospital stay [59, 60]. These methods of procurement are summarized in Fig. 1. However, the practice of NRP is highly controversial due to its methods of perfusion. Some physicians believe that restarting the heart and blood flow to the thoracic and abdominal organs via VA-ECMO brings into doubt the finality of circulatory arrest that is used to declare a donor dead. Opponents of this view will often argue that these methods do not lead to spontaneous resumption of circulation and help donors fulfill their wishes of organ donation [59]. Fig. 1Summary of common methods of donor heart procurement. DBD = Donation after Brain Death; DCD = Donation after Circulatory Death; DPP = Direct Procurement and Perfusion; NRP = Normothermic Regional Perfusion Summary of common methods of donor heart procurement. DBD = Donation after Brain Death; DCD = Donation after Circulatory Death; DPP = Direct Procurement and Perfusion; NRP = Normothermic Regional Perfusion Given these ongoing ethical concerns surrounding in-situ reperfusion and extracorporeal support, alternative procurement strategies have been explored. The rapid recovery with extended ultraoxygenated preservation (REUP) technique, first reported by Williams et al. in 2025, represents a novel approach that allows DCD donor hearts to be recovered without any heart reanimation and without machine perfusion [61]. The technique involves a modified flush circuit primed with 2 L of a solution containing packed red blood cells and del Nido cardioplegia among additional additives. After declaration of circulatory death, the oxygenated perfusate is delivered as an extended flush over 10 to 12 min at a mean aortic root pressure of 80 mm Hg. The heart is then placed in static cold storage at 10 °C for transport without any period of reanimation or machine perfusion [61]. In the initial report of three cases, all hearts were transplanted successfully with normal biventricular function, no evidence of acute cellular or antibody-mediated rejection, and excellent early postoperative outcomes with no adverse events during the perioperative period [61]. However, these cases were limited to younger donors between the ages of 16–30 with ischemic times < 4 h. A subsequent expanded case series of 24 REUP-recovered DCD hearts demonstrated 30-day survival of 96%, with only 1 patient (4%) developing severe PGD and 1 patient (4%) with secondary graft dysfunction (SGD). The mean donor age was 32 years, with 38% of donors older than 40 years, and 60% of donor hearts had a total ischemic time longer than 4 h, including one that reached 8 h [62]. These results demonstrate the safety and feasibility of REUP across a broader population of donors and recipients than initially described, including older donors and allografts with prolonged ischemic times [62]. The REUP technique offers several practical advantages over existing DCD recovery methods. It can be performed with any perfusion system capable of oxygenating banked blood and servoregulating the delivery of cold solution and can be assembled by a perfusionist without the need for commercial ex-situ devices [61]. It avoids the ethical controversies surrounding NRP by flushing oxygenated preservation solution to the donor heart only, without systemic or brain perfusion and without clamping of the aortic-arch vessels [61]. However, unlike NRP, the REUP technique does not resuscitate abdominal organs, which must be recovered by alternative methods. Overall, the emergence of non-reanimation-based strategies such as REUP may represent a fundamental paradigm shift in DCD heart transplantation, as current outcomes continue to match or exceed those achieved with traditional reanimation-based approaches. However, more study in this area is warranted. In parallel with these evolving procurement strategies, the use of DCD donors has increased in recent years. According to the UNOS, DCD comprised 23.75% of all donor hearts in 2025 [1]. DCD has tremendous potential to significantly increase the heart donor transplant pool and reduce waiting times [63, 64]. Noterdaeme et al. found that expanding the use of DCD may increase heart transplants by 15% and potentially reduce deaths on waiting lists by 40% [65]. However, DCD has disadvantages compared to DBD. Due to the need to confirm circulatory death followed by a standoff period, hearts from DCD donors are at increased risk of myocardial injury from factors including hypoxemia, pulmonary vasoconstriction, and right ventriclar distension [66]. However, DCD donors may avoid a Cushing response where a massive release of cytokines after brain death can harm the donor heart. This is due to clamping of vessels from the brain [67]. In animal studies, this phenomenon has shown potential to damage the cardiac tissue and promote inflammation through altering surface antigens [68]. Thus, there is potentially less concern for primary graft dysfunction in DCD donation [69]. The recent multicenter Donors after Circulatory Death Heart Trial compared 6-month outcomes in 80 DBD transplants preserved with static cold storage and 86 DCD transplant preserved with the TransMedics OCS. This study found no significant difference in the risk-adjusted 6-month survival between the DBD group [94% (95% confidence interval [CI], 88 to 99)] and the DCD group [90% (95% CI, 84 to 97)]. Additionally, there was no significant difference in the mean number of serious graft-related adverse events within the first 30 days of transplantation between both groups. However, more moderate or severe PGD was seen in the DCD group (18/80, or 22%) compared to the DBD group (8/84, or 10%) within 30 days of transplantation. Of these instances of PGD, two cases resulted in re-transplantation, but both occurred within the DBD group [70]. It should be noted that this study was supported by TransMedics. However, it was peer-reviewed and published in the New England Journal of Medicine. While more long-term studies are warranted, anesthesiologists should be wary of PGD occurring shortly after transplantation, especially in DCD transplants. Another possible concern centers around the possibility of DCD heart recipients needing prolonged mechanical support. A review of limited data by White et al. found that roughly 29% of recipients required temporary mechanical support [71]. In these patients, mechanical support was started anywhere after the first TEE assessment during weaning from cardiopulmonary bypass to one day post-op [72, 73]. Additionally, all patients were weaned successfully from mechanical support and most had normal biventricular function on echocardiogram [71]. It should also be noted that DCD recipients are less likely to require pre-transplant Mechanical Circulatory Support (MCS) when compared to DBD recipients [74, 75]. As a result, cardiac anesthesiologists must be vigilant about assessing cardiac function immediately post-bypass and prepare for pharmacologic and mechanical support as necessary in patients who have DCD transplants. Supplemental cardioplegia Traditionally, myocardial preservation after procurement of the heart consists of cold cardioplegia pumped through the organ. However, methods of preservation can often differ, as there are 167 different solutions to choose from and a lack of significant randomized controlled trials comparing these options [76]. Administrative protocols may differ as well. Surgeons have the option to administer one dose of cardioplegia during heart procurement or choose to add supplemental cardioplegia when the organ is implanted into the recipient [77]. Due to a lack of significant clinical data regarding improvements in patient outcomes, however, single dose cardioplegia continues to be the most common method for heart preservation [78]. A recent systematic study by Ribeiro et al. demonstrated that supplemental doses of cardioplegia resulted in significantly reduced perioperative mortality (RR, 0.55; 95% CI, 0.35–0.87; P < 0.01), shorter ICU stays (mean difference, L3.4 days; 95% CI, L5.1 to L1.6; P < 0.01), and decreased incidence of ischemic changes in endomyocardial biopsy samples (RR, 0.49; 95% CI, 0.35–0.69; P < 0.01) [79]. As a result, cardiac anesthesiologists should be aware of which method of heart preservation is utilized in order to better anticipate potential complications during transplantation. Paragonix SherpaPak cardiac transport system (SCTS) Traditional preservation of donor hearts with static cold storage (SCS) has been the standard for donor heart preservation for over six decades. However, conventional ice coolers provide variable and uncontrolled cooling, which increases the risk of freezing injury and limits safe total ischemic time [80, 81]. As transplant centers increasingly accept expanded criteria donors, the limitations of traditional ice storage have become more clinically significant. The development of temperature-controlled static preservation systems has emerged as a practical strategy to mitigate this risk and facilitate the safe utilization of expanded criteria donor hearts. One prevalent example of this technology is the Paragonix SherpaPak Cardiac Transport System (SCTS). This is an Food and Drug Administration (FDA)-approved single-use device that maintains the donor heart between 4 °C and 8 °C during transportation, providing more stable and optimal temperature regulation compared to conventional ice coolers [80]. As a result, the SCTS has become the most common method of static preservation in the United States [82]. In the GUARDIAN-Heart Registry, the largest real-world registry focused on organ preservation, SCTS utilization among 1,261 US adult heart transplants was associated with significant reductions in severe PGD (ice 10.8% vs. SCTS 6.8%, p = 0.015) and severe right ventricular dysfunction (ice 9.9% vs. SCTS 6.1%, p = 0.022) when compared to SCS [82]. In the propensity-matched cohort, SCTS use was associated with significantly lower mortality beyond 2 years (ICE 10.5% vs. SCTS 5.7%, p = 0.042), with higher 2-year Kaplan–Meier survival probability observed in the SCTS group (p = 0.022) [82]. Before this study, no advanced heart preservation strategy had demonstrated a significant survival benefit in heart transplant recipients [82]. A subgroup analysis of the GUARDIAN-Heart Registry specifically evaluated 330 extended criteria donor hearts (193 SCTS, 137 ice) and found that SCTS reduced the rate of severe PGD by over 50% compared to SCS (6.2% vs. 13.9%, p = 0.022) [83]. Post-transplant mechanical circulatory support utilization (22.3% vs. 35.0%, p = 0.012) and new ECMO/VAD requirement (7.8% vs. 15.3%, p = 0.033) were also significantly reduced in the SCTS cohort, with similar one-year survival between groups (92.9% vs. 89.6%, p = 0.27) [83]. These findings are particularly relevant given that the SherpaPak cohort had significantly greater distances traveled and longer total procurement times, yet still achieved superior graft function outcomes. The benefits of temperature-controlled storage also extend to high-risk recipient populations. Among patients with durable left ventricular assist devices (LVADs) undergoing heart transplantation, SCTS use was associated with reduced PGD (adjusted OR 0.56; 95% CI 0.32–0.99; p = 0.045) and severe PGD (adjusted OR 0.31; 95% CI 0.13–0.75; p = 0.009) compared to traditional SCS [84]. Additionally, analysis of recipients bridged with various MCS strategies (VAD, IABP, and ECMO) found that SCTS use resulted in significantly lower rates of moderate/severe RV dysfunction compared to SCS across bridging modalities [85]. TransMedics organ care system (OCS) The TransMedics OCS is the only FDA-approved device in the United States for extracorporeal perfusion and preservation of donor hearts in both DBD and DCD transplants. It preserves the donor heart in a near physiologic, normothermic, and beating state, which results in a significantly reduced cold ischemic time when compared to SCS. Another advantage of the OCS is that it allows continued evaluation of the donor heart’s viability by measuring arterial and venous lactate levels, aortic pressure, and coronary blood flow [86]. These methods that aim to reduce ischemic and reperfusion injury are shown in Fig. 2. Cardiac anesthesiologists need to know that unique, recent data from the OCS such as lactate levels, aortic pressure, and coronary blood flow can be obtained before transplants occur. In the future, this data may assist cardiac anesthesiologists in predicting short and long-term clinical outcomes after OCS. Fig. 2Conventional and novel approaches to prevent ischemic and reperfusion injury during heart transplantation Conventional and novel approaches to prevent ischemic and reperfusion injury during heart transplantation Multiple studies have found that survival for OCS is equivalent or superior to SCS in the short term (usually 30 days post-transplant) [87, 88]. In the EXPAND/EXPAND + CAP (Extended criteria trials for donor heart analysis + Continued Access Program) trials, extended criteria donor hearts (those with factors such as higher donor age, mild CAD, or extended resuscitation) from DBD transplants were preserved in the OCS instead of normal SCS. The EXPAND + CAP results demonstrated primary effectiveness (30-day survival and freedom from severe ISHLT-defined PGD) that significantly exceeded the predefined 65% performance goal (92.0% [95% CI: 86.4%−95.8%]; P < 0.0001) [89]. Specifically, reported incidence of severe PGD was 6.7%, which aligns with recent reported rates of severe PGD in heart transplantation [90]. These studies show that OCS can increase the donor pool by potentially allowing increased procurement of marginal hearts for transplantation while minimizing short-term mortality and complications such as PGD. However, OCS can be expensive and resource intensive. Each use of this device costs around $40,000 to $80,000, requires a staff of five additional people, and requires more complicated transport compared to SCS [91, 92]. Overall, expanding the donor pool by utilizing marginal hearts from DCD donors may present new perioperative challenges to cardiac anesthesiologists involved in the heart transplant. Thus, perioperative monitoring will be crucial in detecting these complications as early as possible. Recently, a group from Stanford performed the first 10 human “Beating Heart Transplant Procedures Using Organs From Donors With Circulatory Death”. Normally in DCD transplants, there are two periods each of cardioplegic arrest, warm ischemia, and cold ischemia. The authors in this study were able to achieve uninterrupted coronary perfusion through “simultaneously cannulating the donor heart for coronary perfusion from the recipient cardiopulmonary bypass circuit while the allograft was perfused on an ex vivo normothermic perfusion platform and then sewing the graft in while beating” [93]. This method allows the donor heart to be transplanted in a beating state and eliminates the additional warm and cold ischemic period normally found in DCD heart transplants. Afterwards, the team found that the median follow-up was 97.5 days (range: 14.0–293.0). All 10 patients (100%) were discharged home and survived, with no need for postoperative ECMO, intra-aortic balloon pump (IABP), or RVAD. The median hospital stay was 29.0 days (interquartile range: 24.0–35.0), and the mean was 29.9 days (standard deviation: 12.8). The median ICU stay was 11.5 days (range: 3.0–33.0), and the mean was 10.6 days (standard deviation: 4.7) [93]. Hopefully advances in this technique can lead to better long-term outcomes as well. Hypothermic oxygenated machine perfusion (HOPE) Hypothermic oxygenated machine perfusion (HOPE) is a novel preservation strategy that maintains the donor heart in a resting, non-beating state with continuous oxygenated perfusion at 8 °C to 12 °C using a non-blood-based perfusate [81, 94]. Unlike the OCS, which reanimates the heart in a warm beating state, HOPE preserves the heart under hypothermic conditions while mitigating the ischemia inherent to static cold storage by providing continuous oxygen delivery to the myocardium [81].The technology, also referred to as non-ischemic heart preservation (NIHP), underwent a clinical feasibility study between 2017 and 2018 demonstrating event-free 6-month survival in six recipients [95]. The first multicenter clinical investigation of HOPE for donor hearts, conducted in Australia and New Zealand, enrolled donor hearts with projected preservation times of 6 to 8 h - durations that would ordinarily prohibit use or be expected to lead to increased morbidity with SCS [96]. Among 29 cases, the mean preservation time was 414 min, with the longest reaching 8 h and 47 min. There was 100% survival at 30 days, with only one case of PGD and one case of SGD. 30-day survival was superior to the ISHLT comparator group despite substantially longer preservation times [96]. The landmark European randomized controlled trial (NIHP2019) subsequently provided the strongest evidence for HOPE in heart transplantation. This multinational, multicenter, randomized, controlled, open-label trial enrolled 229 patients across 15 transplant centers in eight European countries, with donor age inclusion criteria of 18 to 70 years — a notably broad range that included a generally higher-risk donor population than is typical in many US centers [81]. All 100 donor hearts preserved with HOPE were transplantable after perfusion. The composite primary endpoint (cardiac-related death, moderate or severe PGD, acute cellular rejection ≥2R, or graft failure within 30 days) was found in 19% of the HOPE group versus 30% of the SCS group, resulting in a 44% risk reduction (HR 0.56; 95% CI 0.32–0.99; log-rank p = 0.059) [81]. While the primary endpoint did not reach statistical significance by the log-rank test, sensitivity analyses adjusting for randomization strata (46% risk reduction, HR 0.54; 95% CI 0.30–0.96) and for the random clustering effect of study site (49% risk reduction, HR 0.51; 95% CI 0.28–0.91) demonstrated significant benefit. The most pronounced effect was on PGD specifically: only 11% of HOPE patients developed PGD compared to 28% in the SCS group (RR 0.39; 95% CI 0.20–0.73). Major adverse cardiac transplant events were also significantly reduced with HOPE (18% vs. 32%; RR 0.56; 95% CI 0.34–0.92) [81]. Importantly, the investigators noted that the positive effect of HOPE was demonstrated for both standard and high-risk donor hearts (donors with diabetes, hypertension, cardiopulmonary resuscitation events, coronary angiogram irregularities), and that many of these organs might not have been used in other settings. HOPE is also being explored for DCD heart recovery. The first North American experience using the XVIVO Perfusion HOPE device for direct procurement and perfusion of DCD cardiac allografts reported five transplantations with an average preservation time of 298 min, no observed cases of severe PGD, and all patients surviving to discharge alive at last follow-up [97]. These findings are a part of the ongoing Prospective, Multicenter, Single-arm, Open-label Study of Hearts Transplanted After Non-ischemic Heart Preservation From Extended Donors (PRESERVE) Trial. This is an FDA Investigational Device Exemption clinical trial in the United States (NCT05881278) that aims to evaluate the XVIVO Heart Preservation System utilizing extended criteria donor hearts exclusively in DCD transplants [98]. If validated in such studies, HOPE may represent a valuable addition to emerging strategies aimed at expanding the DCD donor pool. Perioperative monitoring During cardiac transplant, anesthesiologists will have to utilize invasive monitoring in the forms of arterial lines, pulmonary artery catheters (PACs), and transesophageal echocardiography (TEE) to monitor patient hemodynamics and/or cardiac function. In addition, near infrared cerebral saturation can be utilized to decrease the risk of neurological injury during heart transplantation [99]. Invasive arterial lines Arterial lines are utilized in recipients during cardiac transplants since this patient population can be susceptible to hemodynamic instability and require frequent blood gas sampling. Additionally, the radial artery benefits from collateral circulation via the palmar arches, theoretically reducing the risk of ischemia to the hand [100]. However, the radial artery is not without its challenges. One major drawback is its tendency to misrepresent central aortic blood pressure due to the central-to-radial artery pressure gradient. This phenomenon occurs when the radial artery pressure becomes significantly lower than the central aortic pressure. This gradient can lead to significant discrepancies, especially after cardiopulmonary bypass [101, 102]. Such discrepancies can result in inaccurate pressure readings, potentially leading to improper management of hemodynamic states and adverse outcomes [103]. As a result, cardiac anesthesiologists can check and compare aortic root pressure to radial artery pressure when they suspect this phenomenon is occurring. In terms of safety, while radial artery catheterization is generally considered minimal risk, there are concerns about its complications, particularly in patients with incomplete palmar arches, who are at higher risk for ischemia [100]. This is comparable to the risks associated with brachial and femoral artery catheterization. Studies have shown that complications such as ischemic damage, while more common in brachial and femoral catheterization, are relatively rare across all arterial sites [104–106]. Pulmonary artery catheters PACs are used to directly or indirectly evaluate a wide range of hemodynamic measurements, such as right atrial pressure, right and left ventricular end-diastolic pressure, pulmonary artery pressure, and mixed venous oxygen saturation (SvO2). The measurement of these variables is vital due to the unique physiology of the cardiac transplant recipient. Often, they will exhibit impaired cardiac pumping and vascular function due to a variety of insults including anesthetic agents, reperfusion injury, surgical damage, and dysfunctional autonomic input [107]. Additionally, during cardiopulmonary bypass, these patients may experience wide fluctuations in whole body oxygen consumption (VO2) and oxygen delivery (DO2) due to factors such as reperfusion, body temperature changes, and pump flow rate [108]. However, there are still caveats to using PACs. Since inserting such devices is invasive in nature, patients may experience complications such as bleeding, pneumothorax, and infection. Additionally, insertion and removal of the catheter may result in arrhythmias and damage to the pulmonary artery and right heart valves [109]. PACs, due to their complex setup and output of vast amounts of real-time data, can also cause clinicians to misinterpret data and subsequently provide inefficient and/or incorrect management [107]. TEE Heart transplantation presents many unique challenges to cardiac anesthesiologists due to the complex nature of the surgery. Each step of this procedure presents new potential for complications, so it is vital to monitor the hemodynamics of the recipients and recognize the early warning signs for setbacks. Before induction, a PAC is placed to monitor cardiac output and pulmonary artery pressures. This is crucial since irreversible pulmonary hypertension is a strong contraindication to heart transplant. This should be suspected with a pulmonary artery systolic pressure > 50 mm Hg in combination with either a pulmonary vascular resistance (PVR) > 3 Woods units or a transpulmonary gradient of > 15 [110]. To potentially prevent the PAC from being caught on the superior vena cava anastomosis in bicaval HT’s, the catheter should be withdrawn at least 20 cm back into its sterile sheath [111]. TEE can be utilized to confirm the final location of the PAC tip in the donor heart and prevent over-wedging given any potential mismatch between donor and recipient heart size. Cardiac anesthesiologists also need to be aware that once the recipient heart containing the PAC is removed, the infused medications need to be connected to the sideport of the PAC to ensure they reach the systemic circulation. Cardiac anesthesiologists can continue to use valuable information from TEE in the perioperative setting as well. LV dysfunction in donor hearts is often a result of insufficient myocardial preservation combined with long ischemic time. If this is seen, cardiac anesthesiologists can manage this complication with inotropes and/or fluid management and alert the rest of the team immediately of this new finding. RV dysfunction can also be evaluated on TEE, and is often the result of long ischemic time, air in the right coronary artery, physical compression during chest closure, or increased PVR. RV systolic dysfunction should be suspected when there is either RV dilation with a smaller LV in the mid-esophageal 4-chamber view, tricuspid annular plane systolic excursion (TAPSE) < 17 mm, fractional area change < 35%, or maximum velocity in the lateral tricuspid annulus during systole (S’) < 10 cm/s [112]. TEE also has a significant role in monitoring for other complications besides ventricular dysfunction. Before weaning from CPB, the cardiac anesthesiologist should look for air in the left ventriclar apex and sites of anastomosis to prepare for potential de-airing. After CPB discontinuation, the great vessels should be examined for signs of stenosis or thrombus. Doppler flow at the aortic and pulmonic levels should be normal, even with small size mismatches between the donor and recipient vessels [113]. For reference, normal doppler velocity is < 1.4 m/s at the ascending aorta and < 1 m/s at the pulmonary artery [114]. After extubation, a thinner TEE probe or surface ultrasonography with an RV focus position can also be utilized to assess RV function. Overall, using these different methods of invasive monitoring will help cardiac anesthesiologists with managing the complexities of marginal hearts as donor and recipient pools are expanded. Immediate challenges facing anesthesiologists post-transplant Vasoplegia As the donor and recipient pools expand, cardiac anesthesiologists must be prepared for the increased risk for post-transplant complications as more marginal donor organs and recipients become eligible for this procedure. One common complication is vasoplegia, which is a state following heart transplant marked by significant systemic hypotension and reduced systemic vascular resistance (SVR) despite a normal or high cardiac index, standard vasopressor support, and fluid resuscitation. This condition is a significant complication that can be common during heart transplant, as several reviews have found incidences that ranged from 11% − 34% [115, 116]. There are various risk factors for this condition. Batchelor et al. found that patients who developed vasoplegia were generally older (52.7 ± 10.2 vs. 46.8 ± 12.7 vs. 44.4 ± 11.3 years, P = 0.02), more likely to have been bridged with LVAD (n = 42) (62.5% vs. 32.3% vs. 37.5%, P = 0.03), and more likely to have pre-existing chronic kidney disease (18.8% vs. 32.3% vs. 3.1%, P = 0.01) [117]. While the exact pathophysiology of this condition is not known, several factors such as adenosine, nitric oxide, prostaglandins, and the renin-angiotensin-aldosterone system have been suggested to play a role [118]. Thus, for cardiac anesthesiologists, the prevention of PGD and subsequent vasoplegia are vital for long-term survival. Diagnosis Currently, there is no consensus for the definition of vasoplegia, though most are similar. Many definitions include criteria such as [119]: MAP < 50 mmHg.Pulmonary Wedge Pressure < 12 mmHg.SVR < 800 dynes/s/cm5.Cardiac Index > 2.5 L/min.Unresponsive to fluids and vasopressors. MAP < 50 mmHg. MAP < 50 mmHg. Pulmonary Wedge Pressure < 12 mmHg. Pulmonary Wedge Pressure < 12 mmHg. SVR < 800 dynes/s/cm5. SVR < 800 dynes/s/cm5. Cardiac Index > 2.5 L/min. Cardiac Index > 2.5 L/min. Unresponsive to fluids and vasopressors. Unresponsive to fluids and vasopressors. In a review of case report series (n = 12), Qin et. al. found that nine (75%) patients experienced vasoplegia intraoperatively [120]. Of this group, vasoplegia was seen during cardiopulmonary bypass in five (55.56%) patients, during weaning from bypass in 2 (22.22%) patients, and after discontinuation of bypass in 2 (22.22%) patients (Fig. 3). As a result, cardiac anesthesiologists should be especially wary of vasoplegia once CPB is started and should continue to be vigilant during and immediately after bypass is discontinued. Fig. 3Time to onset of vasoplegia in 12 different heart transplant recipients. Acronyms: ICU, intensive care unit; CPB, cardiopulmonary bypass Time to onset of vasoplegia in 12 different heart transplant recipients. Acronyms: ICU, intensive care unit; CPB, cardiopulmonary bypass Management Catecholamine-sensitive vasoplegia Currently, there are no society guidelines for the management of vasoplegia, though treatment is generally well-established. Once a patient is suspected to have vasoplegia, vasoactive drugs and IV fluids are used in initial management of the condition. Norepinephrine is recommended internationally as the first-line vasopressor for septic shock [121]. Alternative pharmaceutical options include other catecholamines such as epinephrine and dopamine, as well as non-catecholamines including vasopressin, methylene blue, angiotensin II, hydrocortisone (though recipients already receive high-dose steroids), hydroxocobalamin (Vitamin B12), and Vitamin C. These agents are summarized in Table 1. While catecholamines are often utilized for vasoplegia, high doses may lead to increased myocardial oxygen demand, oxidative stress, arrhythmias, and an increased risk of organ damage due to significant vasoconstriction [122]. Additionally, some patients may develop catecholamine-resistant vasoplegia, which was found to have a mortality rate in one study of 25% [123]. Table 1Pharmacologic management of vasoplegiaPharmacologic agentMechanism of actionNorepinephrineStrong α1 and α2 agonismModerate β1 agonismEpinephrineStrong α1 and α2 agonismStrong β1 agonismPhenylephrineStrong α1 and α2 agonismDopamineDose-dependent adrenergic and α1 agonismVasopressinV1 agonismMethylene BlueInhibits guanylyl cyclase and NO synthaseHydrocortisoneGlucocorticoid and mineralocorticoid actionInhibition of pro-inflammatory cytokinesAngiotensin IIAT1 agonism and aldosterone releaseVitamin B12Inhibition of NO and endothelial NO synthaseVitamin CCatecholamine synthesis cofactor Table 1Pharmacologic management of vasoplegiaPharmacologic agentMechanism of actionNorepinephrineStrong α1 and α2 agonismModerate β1 agonismEpinephrineStrong α1 and α2 agonismStrong β1 agonismPhenylephrineStrong α1 and α2 agonismDopamineDose-dependent adrenergic and α1 agonismVasopressinV1 agonismMethylene BlueInhibits guanylyl cyclase and NO synthaseHydrocortisoneGlucocorticoid and mineralocorticoid actionInhibition of pro-inflammatory cytokinesAngiotensin IIAT1 agonism and aldosterone releaseVitamin B12Inhibition of NO and endothelial NO synthaseVitamin CCatecholamine synthesis cofactor Pharmacologic management of vasoplegia Strong α1 and α2 agonism Moderate β1 agonism Strong α1 and α2 agonism Strong β1 agonism Glucocorticoid and mineralocorticoid action Inhibition of pro-inflammatory cytokines Due to these concerns with catecholamines, non-catecholamine drugs are often used synergistically. Vasopressin in particular has become popular to use for augmentation for catecholamine resistance. The Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery (VANCS) trial (n = 300) demonstrated lower rates of all-cause mortality/severe complication of vasopressin when compared to norepinephrine (32% vs. 49% respectively, p = 0.0014). Thus, this study suggested that vasopressin could be considered for first-line use for vasoplegia [124]. However, data regarding its use in catecholamine-resistant vasoplegia is still very limited. Catecholamine-resistant vasoplegia Another option to consider if a patient fails catecholamine and vasopressin therapy is angiotensin II (AT2). In 2017, the phase 3 Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) trial explored whether adding AT2 in combination with traditional vasopressors could improve blood pressure in patients with catecholamine-resistant vasodilatory shock. Here, 69.9% of patients in the AT2 group reached the primary endpoint of an increase of 10 mmHg in MAP or an improvement to at least 75 mmHg within 3 h (at a starting AT2 dose of 20ng/kg/min with titration every 5 min up to 200ng/kg/min). Meanwhile, 23.4% of patients in the placebo group were able to reach these thresholds (odds ratio, 7.95; 95% confidence interval [CI], 4.76 to 13.3; P < 0.001) [125]. In a post-hoc analysis of ATHOS-3 that focused solely on 16 patients that developed vasoplegia after undergoing cardiac surgery with CPB, Klijian et al. found that the ATHOS-3 MAP goals were met in 88.9% of patients in the AT2 group in comparison to 0% of those in the placebo group (p = 0.0021). Additionally, they found that the median standard-of-care vasopressor dose at hour 12 decreased from baseline (20ng/kg/min) in 76.5% of patients in the AT2 group compared to 7.8% in the placebo group (p = 0.0013) [126]. Other studies regarding the use of AT2 in conjunction with traditional vasopressor therapy in vasodilatory shock found significant MAP improvement and decreased dosage of vasopressors in patients requiring MCS for cardiac failure, as well as greater rates of survival and discontinuation of renal replacement therapy in those who experienced acute kidney injury after developing vasoplegia [127, 128]. It should be noted, however, that 12.9% of patients in the AT2 group developed venous thromboembolism (VTE) compared to 5.1% of patients in the control group (p = 0.02) [125]. Thus, it is important to exercise caution in its use in patients undergoing MCS without anticoagulation. Recently, a case series of 4 patients by Cutler et al. demonstrated the potential for AT2 to be used perioperatively in heart transplants, early during bypass, during weaning from bypass, and postoperatively. These findings illustrate the possible use of AT2 on bypass, which is much earlier compared to conventional administration [129]. Overall, cardiac anesthesiologists currently do not have guidance regarding the appropriate timing for adding AT2 for patients with vasoplegia. In the future, a randomized clinical trial regarding this timing for cardiac surgery and heart transplant would be helpful in determining when to administer this drug. Currently, cardiac anesthesiologists should recognize the potential of AT2 to significantly reduce morbidity and mortality in patients with vasoplegia but should exercise caution for those with higher risk for VTE and consider alternative treatment options in this patient population. A final treatment option to consider is Vitamin C (ascorbic acid), which serves as a cofactor for catecholamine synthesis. In 2017, Marick et al. explore whether a combined hydrocortisone, ascorbic acid, and thiamine (HAT) therapy would improve outcomes in patients with septic shock. When compared to the control group, the treatment group demonstrated lower rates of mortality (8.5% vs. 40.4%, p = < 0.001), decreased vasopressor duration (18.3 h vs. 54.9 h, p < 0.001), and lower incidence of acute kidney injury (10% vs. 38%, p < 0.001) [130]. However, several follow-up studies were not able to replicate these findings in regard to HAT therapy and instead found equivocal results for septic shock [131, 132]. In 2023, the VALENCIA trial explored whether intravenous Vitamin C without other additional therapies would be effective in patients with vasoplegia. Again, results were equivocal for patient morbidity and mortality [133]. A 2020 random, double-blind randomized control trial by Yanase et al. that explored using intravenous Vitamin C specifically in cardiac surgery patients with vasoplegia post-CPB also found no significant differences in metrics such as 30-day mortality, organ dysfunction, and mean norepinephrine doses [134]. For cardiac anesthesiologists, this means that Vitamin C should primarily be considered when other treatment options have already been exhausted. Acute right-sided heart dysfunction and/or failure The donor heart is not accustomed to increased afterload associated with elevated pulmonary artery pressure and pulmonary hypertension. RV dysfunction can also be caused by transplant-specific risk factors such as reperfusion injury and cold ischemic time, as well as surgical causes such as mechanical obstruction at the pulmonary artery or both venous anastomoses and donor-recipient size mismatch [135, 136]. In recipients with pulmonary hypertension, which is defined as PVR greater than 2.5 Wood units, mean pulmonary arterial pressure (mPAP) > 25 mmHg, and/or transpulmonary gradient (the difference between mPAP and PCWP, abbreviated TPG) greater than 12 mmHg, the donor RV may experience dysfunction after pumping against an increased pulmonary afterload. Since the RV is thin-walled and thus more reactive to changes in volume and pressure, it is susceptible to dilation, reduced contractility, and tricuspid regurgitation [136, 137]. As a result, many transplant centers will measure preoperative PVR in the recipients to stratify the risk for right heart failure after transplant. Several studies have found that elevated preoperative PVR, TPG, or a combination of both have been associated with higher morbidity and mortality post-transplant [138–140]. Diagnosis and evaluation There is no single test, imaging, or laboratory study that can provide a definitive diagnosis of acute RV dysfunction/failure immediately post-transplant. Instead, anesthesiologists must be wary of signs that such a complication is occurring using measures such as Right Atrial Pressure to Pulmonary Capillary Wedge Pressure (RA/PCWP) ratio. A relatively new hemodynamic measure, the pulmonary artery pulsatility index (PAPi), has been utilized for assessing the function of the right heart in the settings of pulmonary hypertension, heart failure, and cardiogenic shock [141, 142]. PAPi can be determined during invasive right heart catheterization and is calculated as:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\frac{Pulmonary\:artery\:systolic\:pressure-\:pulmonary\:artery\:diastolic\:pressure}{Right\:atrial\:pressure}\:$$\end{document} A lower score is associated with worse right heart function. Several recent studies have found an association between low preoperative PAPi and morbidity and/or mortality post-heart transplant. However, there seems to be no data regarding the direct relationship between PAPi and acute right heart failure in heart transplant recipients. Wagner et al. found that in heart transplants performed in patients with pulmonary hypertension between 2009 and 2019 in EuroTransplant member states (n = 10,465), low PAPi (OR = 2.24, p < 0.001) was associated with graft failure [140]. Bellettini et al. found that among 657 transplant recipients at two Italian transplant centers between 2000 and 2018, patients with pre-transplant right ventricular dysfunction (RVD) defined as PAPi of < 1.68 had significantly lower 1-year post-transplant survival (77.8% vs. 87.1%, P = 0.005), MCS during transplant (hazard ratio 2.0, 95% confidence interval, 1.3–3.1), and PGD (hazard ratio 1.7, 95% confidence interval 1.02–3.30). RVD/low PAPi was also associated with decreased 1-year survival in recipients with normal PVR defined as < 3 Woods units (76.9% vs. 88.3%, P = 0.003), but not in recipients with elevated PVR > 3 Woods units (78.6% vs. 83.2%, P = 0.49) [141–143]. This means that cardiac anesthesiologists can use this novel measurement to prepare for possible complications immediately post-transplant such as the need for MCS and managing PGD. Additionally, new noninvasive methods to evaluate for RV failure and dysfunction are on the horizon. 3D echocardiography has often been shown to better evaluate RV function than 2D due to its ability to better assess complicated geometry and contractility, potentially adding another tool for perioperative monitoring in the future [144–146]. Management Anesthesiologists can manage RV dysfunction and/or failure immediately post-transplant in a myriad of ways. They should seek to minimize RV afterload, usually with pulmonary vasodilators. However, they should first ensure the patient is well oxygenated, sedated, and well-ventilated. Acidosis and hypercarbia should be avoided, with a goal of a PCO2 less than 40 torr. Finally, mean airway pressure should be minimized by avoiding positive end expiratory pressure and utilizing a short inspiratory to expiratory ratio [147]. Once these goals have been met, it is appropriate to start pulmonary vasodilation. Inhaled nitric oxide (iNO) is a popular option due to its ease of administration but presents with the drawback of high costs. A starting dose of 10 ppm can be adjusted up to 40 ppm in 5 ppm increments. Once the patient is stabilized, they can be weaned off the iNO in 5 ppm increments or less, depending on how they tolerate the reduced doses. However, anesthesiologists should be wary of potential rebound increases in PVR if patients are weaned quickly [148]. Thus, it is important to monitor hemodynamics during weaning, especially pulmonary artery pressure and right and left atrial pressure [147]. Attention to maximizing RV free wall function is also crucial, especially in surgeries anticipating a risk of RV failure. This involves instituting inotropic support like milrinone, which also has the benefit of increasing pulmonary vasodilation. However, systemic vascular resistance should be properly managed due to this drug’s ability to decrease interventricular septal support of RV function [147]. Isoproterenol, a non-selective beta agonist alternative, also has a similar effect in pulmonary and peripheral vasodilation. Another inotrope, Dobutamine, is a nonselective beta agonist with minimal agonistic activity at alpha receptors. This avoids significant vasoconstriction but can lead to tachycardia and atrial arrhythmia at higher doses. The emergence from anesthesia followed by extubation can stress RV function and cause RV dysfunction to occur or recur. If heart failure occurs post-transplant, additional sedation for 12–24 h may be considered to allow RV function to recover and PVR to improve. However, spontaneous breathing after awakening is also valuable, as this can decrease pulmonary artery pressure, resulting in better RV function [147]. Thus, the timing of extubation after heart transplant and its effect on RV function in the new heart is a critical decision for cardiac anesthesiologists and ICU physicians to make. Special considerations should also be taken for patients who are placed on LVAD after transplantation. LVADs can potentially contribute to RV failure since interaction between the two ventricles is altered, leading to a decrease in RV contractility [149, 150]. In these cases, it may be appropriate to reduce LVAD flow to allow more LV filling and subsequent interaction with the RV [147]. Refractory RV failure in the transplanted heart can be managed with mechanical support though RVADs. It is important to assess LV function and adjust RVAD settings as necessary so that the LV is not overwhelmed. RVADs should then be weaned after hemodynamic monitoring shows appropriate function. Once this occurs, patients are recommended to be sedated at least 24 h to allow for further improvement in RV function and pulmonary vascular resistance [147]. Ultimately, however, ECMO may be required as RV failure rarely occurs in isolation and is often accompanied by left ventricular dysfunction or pulmonary failure. ECMO can address the circulatory collapse and ensure adequate oxygenation and perfusion when RVAD alone is insufficient. Primary and secondary graft dysfunction Cardiac anesthesiologists need to know the criteria to diagnose PGD immediately post-transplant, especially when the rest of the transplant team is still in the room. In general, PGD is described as ventricular donor graft dysfunction occurring within 24 h of transplantation that leads to reduced cardiac output and hypotension that ultimately results in poor circulatory function. In 2014, the ISHLT published a consensus set of guidelines for the definition, diagnosis, and management of PGD [151]. Here, PGD is categorized as left ventricular (L-PGD) and right ventricular (R-PGD), with L-PGD also including biventricular dysfunction. L-PGD can further be classified into mild, moderate, or severe based on the patient’s need for inotropes or MCS, as seen in Table 2. Table 2ISHLT classification of PGDDefinitionDiagnostic criteriaL-PGDLeft ventricular and biventricular dysfunctionMildLVEF ≤ 40% or 1 hr of CI < 2 L/min/m2, RAP > 15 mmHg, and PCWP > 20 mmHg, requires low-dose inotropes ModerateIn addition to mild criteria: MAP < 70 mmHg for >1 hr and high-dose inotropes or requirement for IABP SevereRequires for VA-ECMO, LVAD, or biVADR-PGDIsolated right ventricular dysfunctionRAP > 15 mmHg, PCWP < 15 mmHg, CI < 2 L/min/m2, and TPG < 15 mmHg or PA systolic pressure < 50 mmHg or Requires RVADISHLT, International Society for Heart and Lung Transplantation; PGD, Primary graft dysfunction; L-PGD, left ventricular primary graft dysfunction; LVEF, left ventricular ejection fraction; CI, cardiac index; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; IABP, intra-aortic balloon pump; VA-ECMO, venoarterial extracorporeal membrane oxygenation; LVAD, left ventricular assist device; biVAD, biventricular assist device; R-PGD, right ventricular primary graft dysfunction; TPG, transpulmonary gradient; PA, pulmonary artery; RVAD, right ventricular assist device Table 2ISHLT classification of PGDDefinitionDiagnostic criteriaL-PGDLeft ventricular and biventricular dysfunctionMildLVEF ≤ 40% or 1 hr of CI < 2 L/min/m2, RAP > 15 mmHg, and PCWP > 20 mmHg, requires low-dose inotropes ModerateIn addition to mild criteria: MAP < 70 mmHg for >1 hr and high-dose inotropes or requirement for IABP SevereRequires for VA-ECMO, LVAD, or biVADR-PGDIsolated right ventricular dysfunctionRAP > 15 mmHg, PCWP < 15 mmHg, CI < 2 L/min/m2, and TPG < 15 mmHg or PA systolic pressure < 50 mmHg or Requires RVADISHLT, International Society for Heart and Lung Transplantation; PGD, Primary graft dysfunction; L-PGD, left ventricular primary graft dysfunction; LVEF, left ventricular ejection fraction; CI, cardiac index; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; IABP, intra-aortic balloon pump; VA-ECMO, venoarterial extracorporeal membrane oxygenation; LVAD, left ventricular assist device; biVAD, biventricular assist device; R-PGD, right ventricular primary graft dysfunction; TPG, transpulmonary gradient; PA, pulmonary artery; RVAD, right ventricular assist device ISHLT classification of PGD ISHLT, International Society for Heart and Lung Transplantation; PGD, Primary graft dysfunction; L-PGD, left ventricular primary graft dysfunction; LVEF, left ventricular ejection fraction; CI, cardiac index; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; IABP, intra-aortic balloon pump; VA-ECMO, venoarterial extracorporeal membrane oxygenation; LVAD, left ventricular assist device; biVAD, biventricular assist device; R-PGD, right ventricular primary graft dysfunction; TPG, transpulmonary gradient; PA, pulmonary artery; RVAD, right ventricular assist device Unfortunately, PGD remains the biggest cause of mortality 30 days post-transplant, and incidence remains high [69]. In a 2018 retrospective study, Nicoara et al. found that the incidence of ISHLT-defined PGD in 317 heart transplants performed at Duke University Medical Center was 31%. Understandably, the rate of 30-day mortality was significantly greater in patients with PGD versus those without (6.06% vs. 0.92%, P = 0.01) [152]. This significant morbidity and mortality demonstrates how crucial it is for cardiac anesthesiologists to make an immediate diagnosis of PGD to minimize this complication’s effect on short and long-term outcomes. Secondary graft dysfunction (SGD) is defined as graft dysfunction with a clear, discernible cause. The most common cause behind SGD is pulmonary hypertension with subsequent RV failure. In their analysis of 900 patients from a multi-center registry, Bourge et al. found pulmonary hypertension and RV failure in 43% of patients with early graft failure [153]. In another retrospective study focusing on 700 heart transplant recipients, the highest early mortality of 14.1% was found to be secondary to RV failure in the patient group with preoperative TPG > 11 mmHg and PVR > 2.8 Wood Units [154]. The second most common cause of SGD is surgical complications, most notably coronary artery occlusion, narrowed anastomosis, pulmonary artery kinking, and significant perioperative bleeding. Finally, the third most common cause is hyperacute rejection occurring minutes to h after donor heart reperfusion [155]. Other common causes of PGD are seen in Fig. 4. Fig. 4Donor, Recipient, and Surgical Contributors to Primary Graft Dysfunction during Heart Transplant. Acronyms: DBD, donation after brain death; DCD, donation after circulatory death Donor, Recipient, and Surgical Contributors to Primary Graft Dysfunction during Heart Transplant. Acronyms: DBD, donation after brain death; DCD, donation after circulatory death Diagnosis and prediction Currently, the diagnosis of PGD is made based on hemodynamic monitoring and the requirement for inotropic support and/or MCS. Several methodologies have been developed to try to predict this phenomenon. RADIAL (developed by Segovia et al. in 2011), incorporated recipient risks into its scoring system. This model is defined as: Right atrial pressure ≥ 10 mmHg, recipient Age ≥ 60 years, Diabetes mellitus, Inotrope dependence, donor Age ≥ 30 years, and Length of ischemic time ≥ 240 min. For a given transplant, one point was added for each of the risk factors above, with a higher score meant to correlate with greater risk of PGD. The RADIAL score’s predictive performance was decent, with a C-statistic of 0.74 [156]. Another scoring system, PREDICTA, was developed in 2019 to take into consideration donor, recipient, and procedural risk factors. This included Preoperative MCS in the recipient, DIabetes mellitus in recipient, Cardiopulmonary bypass time > 180 min, implant Time, and donor Age. PREDICTA seems to have the ability to better predict PGD, with a C-statistic of 0.704 compared to 0.547 for RADIAL [157]. Therefore, cardiac anesthesiologists should use RADIAL and/or PREDICTA to predict the possibility of PGD in high-risk patients. Management Commonly, cardiac anesthesiologists treat PGD beginning with pharmacological management and ending with mechanical support. Inotropic support is usually given by utilizing catecholamines and phosphodiesterase inhibitors. For R-PGD, nitric oxide can also be used to decrease pulmonary vascular resistance. Failing this, the next step is commonly to utilize an IABP, which would immediately classify L-PGD as moderate. If MCS other than an IABP is required, then the current PGD would be classified as severe. The most common methods at this stage would be single ventricle or biventricular assist devices (VAD) and ECMO. Between these two methods of MCS, ECMO is generally preferred due to its better outcomes. This was supported by a 2017 study that demonstrated when compared to ECMO, VAD use in PGD patients was associated with longer cardiopulmonary bypass time, longer support time, and major bleeding. Additionally, significantly more patients were weaned from ECMO support (89%) compared to VAD support (59%) after adequate graft function recovery (p = 0.03) [163]. For cardiac anesthesiologists immediately after transplant, moving from pharmaceutical to mechanical support is a difficult decision, which requires input from the surgeon, anesthesiologist, perfusionist, and critical care personnel. Weaning from MCS Each transplant site may have their own guidelines for when to wean from MCS. Individual anesthesiologists may also rely on their own experiences with the rest of the surgical and ICU team to decide the optimal time to take cardiac transplant patients off such support. Recent studies have shown that the following parameters have been associated with successful weaning of MCS [164–166]: TAPSE at full ECMO > 16 mm.RVEF > 25% (strongest predictor).S’/RVSP > 0.33 at full and minimal flows.Improved PaPi.Low RA/PCWP of < 0.86. TAPSE at full ECMO > 16 mm. TAPSE at full ECMO > 16 mm. RVEF > 25% (strongest predictor). RVEF > 25% (strongest predictor). S’/RVSP > 0.33 at full and minimal flows. S’/RVSP > 0.33 at full and minimal flows. Improved PaPi. Improved PaPi. Low RA/PCWP of < 0.86. Low RA/PCWP of < 0.86. Immediate cardiac autonomic denervation Cardiac anesthesiologists should be aware that there is a lack of both sympathetic and parasympathetic autonomic innervation to the transplanted heart, which leads to many hemodynamic changes immediately post-transplant. The absence of parasympathetic function results in higher resting heart rates ranging from 90 to 110 beats per minute, though some patients may have rates up to 130 beats per minute [17]. The absence of sympathetic innervation results in the loss of cardiac baroreflexes and reflex tachycardia due to vasodilation [167]. Due to the lack of autonomic innervation, both tachyarrhythmia and bradyarrhythmia must be uniquely managed. For tachyarrhythmia, carotid massage and Valsalva maneuver are ineffective for management of paroxysmal supraventricular tachycardia due to the lack of parasympathetic function. Digoxin is also unable to affect vagal activity but can increase contractility by increasing intracellular calcium [167]. Adenosine, on the other hand, has increased potency in such transplanted hearts, and may cause prolonged heart block [17]. Amiodarone and calcium channel blockers are better suited to treat tachyarrhythmia due to their direct action on cardiac tissue [168]. Management of bradyarrhythmia also differs in that anticholinergic management is ineffective. Adrenergic agents are used instead due to their function in cardiac beta-adrenergic stimulation, with isoproterenol usually preferred [17]. Refractory bradyarrhythmia is managed with electrical pacing. During reversal, pyridostigmine and neostigmine should be avoided as they can often cause bradycardia in the transplanted heart. Neostigmine in particular has been reported in the literature to cause asystole and advanced heart block after use [169]. The most recent alternative to acetylcholinesterase inhibitors, sugammadex, has also been shown to cause bradycardia in non-heart transplant patients [170]. Cardiac anesthesiologists need to be aware of the potential for bradycardia and other arrhythmias if reversal is used at the end of heart transplants, especially when there is no backup pacing. Overall, the immediate challenges of vasoplegia, acute RV dysfunction, PGD/SGD, surgical bleeding, and coagulopathy require the full attention of the cardiac anesthesiologist to diagnose and manage all of these potential complications together. Conclusion There is a significant interplay between surgical bleeding, vasoplegia, acute RV dysfunction/failure, and PGD immediately post-transplant. For cardiac anesthesiologists monitoring the patient coming off CPB, they would expect the new heart to perform excellently. However, the factors of vasoplegia, acute RV dysfunction/failure, and PGD combined with surgical bleeding and/or coagulopathy complicate the picture for the cardiac anesthesiologists dealing with one or multiple of these complications occurring together. Initially, one would use pharmacologic support to deal with these issues. Next, mechanical support would be required to augment the pharmacologic support. Given the expansion of both the donor and recipient heart transplant pools, there is increased risk of injury to the donor heart through ischemia and reperfusion injury. Fortunately, there is potential for decreased ischemic time and improved graft preservation with emerging technologies such as normothermic ex vivo perfusion systems (TransMedics OCS), temperature-controlled static storage (Paragonix SherpaPak), and hypothermic oxygenated perfusion (XVIVO device). However, reperfusion injury is still a common issue with no significant novel approaches. Cardiac anesthesiologists should be aware of the new paradigm shift of expanding the heart donor and recipient pools through reevaluating current age restrictions, bridging to transplant with LVADs, wider utilization of DCD transplants, and using appropriate HCV + or COVID+ donor hearts. While these strategies come with their own set of challenges, such as increased incidence of CAV in older donors and myocardial injury in DCD, advancements in technology and careful management can mitigate these risks. The use of devices like the Organ Care System (OCS) for extracorporeal perfusion and preservation of donor hearts is particularly promising. As hospitals refine these and other strategies to expand the donor and recipient pools, cardiac anesthesiologists may have to address immediate perioperative and post-operative complications including vasoplegia, acute right-sided heart dysfunction and/or failure, PGD/SGD, and a variety of technical issues. As a result, they must recognize the early stages of these complications and utilize the wide variety of pharmacologic and/or mechanical support options to address these potentially fatal adverse events. However, the promising long-term outcomes and the ability to increase the possibility of heart transplantation for severely ill patients will make these challenges worth addressing.